Targeting the Default Mode Network: A TMS-fMRI Study

NCT ID: NCT05646732

Last Updated: 2024-04-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-08-02

Study Completion Date

2025-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In post-traumatic stress disorder (PTSD), intrusive, traumatic, autobiographical memories lead to anxiety symptoms. Recent work suggests a new repetitive pulse transcranial magnetic stimulation (rTMS) brain target that might bring relief. Since this proposed target is not well understood, the goal of the study is to use functional magnetic resonance imaging (fMRI) to identify the brain regions and networks that change with rTMS stimulation at this target area in PTSD patients. Ultimately, this would lead to a personalized approach to rTMS treatment of PTSD based on brain imaging that can be used in a future clinical trial.

Participants will be asked to complete psychological testing and questionnaires as well as an initial MRI and two separate TMS-fMRI sessions. Total participation time across all visits is estimated to be five to six hours.

Research participation will take place at VA Palo Alto as well as at Stanford University.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Post-traumatic stress disorder (PTSD) is a devastating illness in which traumatic autobiographical memories are intrusive and lead to anxiety symptoms. These symptoms align with functions of the default mode network (DMN) and, in fact, PTSD patients have abnormalities within the DMN and in its interactions with other networks, notably the salience network and the frontoparietal or central executive network.

Focal repetitive pulse transcranial magnetic stimulation (rTMS) enables neuromodulation of selected brain regions and connected networks to treat specific symptoms, but the brain targets to support this therapy in PTSD are under discovery. A recent analysis uncovered a brain circuit associated with improvement in anxiety and somatic symptoms following the rTMS treatment of depression. The left hemisphere region with the strongest fMRI functional connectivity with this circuit lies within anatomical area 8Av and the DMN. This association suggests that modulating the DMN through stimulation at left 8Av could be a novel rTMS approach for the treatment of anxiety and may help ameliorate anxiety symptoms in PTSD. This target would be novel since the vast majority of clinical trials of rTMS in PTSD have targeted the right frontal regions of the salience and frontoparietal networks instead of the DMN. One potential reason is that the most established nodes of the DMN do not lie directly below the scalp/skull and are thus unreachable by rTMS.

In this proposal, the overall hypothesis is that left area 8Av can serve as a robust, direct brain target for the DMN, thus facilitating therapy for PTSD and the many other disorders involving the DMN. Researchers will use TMS-fMRI in 30 participants with PTSD to test the causal connections between left 8Av and other regions that could mediate a response. Researchers will test the connectivity between 8Av and the inferior parietal lobe (IPL), a region in the DMN involved in context processing, and other nodes of the DMN (e.g., posterior cingulate, ventromedial prefrontal cortex). Pilot data suggests that the functional connection between 8Av and the IPL to be abnormal in people with anxiety relative to controls and that delivering rTMS to these regions ameliorates anxiety. This proposal will also explore whether stimulation at 8Av modulates the anterior insula, a node of the salience network whose functional connectivity predicts benefit from prolonged exposure therapy in PTSD. The TMS-induced BOLD response in these areas to stimulation of 8Av will be measured and compared to conventional seed-based resting-state fMRI functional connectivity analyses that could serve as an alternative marker for capacity for modulation. In addition, researchers will deliver theta burst rTMS (cTBS) stimulation and study how connectivity changes with respect to baseline. The overall goal is to characterize left 8Av functional connectivity in PTSD, and explore the effects of rTMS stimulation parameters. This project will thus provide a mechanistic understanding of rTMS therapy at 8Av, and will reveal the effects of a novel connectivity-based atlas target.

The participants in the study will come for three visits. During the first visit, participants will undergo MRI, psychological, and functional testing that will be used to characterize them as well as confirm their diagnoses and eligibility for the study. Participants will then undergo simultaneous TMS-fMRI and cTBS and fMRI in the second and third visits.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Post Traumatic Stress Disorder PTSD

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

A mechanistic study using TMS-functional MRI
Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

order of presentation is randomized

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TMS-fMRI

Participants will undergo simultaneous TMS-fMRI as part of this study. There will be two locations stimulated: one control region and one target region. Participants will be randomized with respect to the order of receiving stimulation at the locations, but all participants will receive stimulation at both locations as part of the study. All participants will be considered as one group but order effects will be evaluated as an explanatory variable.

Group Type EXPERIMENTAL

TMS-fMRI

Intervention Type DEVICE

Participants will undergo simultaneous TMS and fMRI

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TMS-fMRI

Participants will undergo simultaneous TMS and fMRI

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Simultaneous TMS and fMRI Transcranial Magnetic Stimulation and Functional Magnetic Resonance Imaging

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Between 18 and 55 years of age
* Ability to maintain a Motor Threshold (MT) with single pulse TMS
* Ability to safely and comfortably undergo an MRI and TMS
* Able to read, verbalize, understand, and voluntarily sign the Informed Consent Form prior to participating in any study-specific procedures or assessments.
* PTSD diagnosis according to the DSM 5, as determined by the Clinician administered PTSD scale (CAPS-5) criteria.
* Commitment to maintaining a stable medication regimen between the two fMRI sessions

Exclusion Criteria

* Inability to safely and comfortably undergo an MRI. MRI safety will be determined by the center where MRI's are collected.
* Inability to safely and comfortably undergo TMS. TMS exclusions include any history or condition that puts patients at risk.
* Significant dementia as determined by the Montreal Cognitive Assessments (MoCA)
* Common comorbid disorders of Veterans are allowed, but PTSD must be a primary diagnosis causing significant impairment that could not be accounted for by another diagnosis. Medical or mental health conditions that interact with or confound interpretation of PTSD symptoms and anxiety would be exclusionary.
* Being in urgent need of care that would make participation impossible
* Currently taking medications that increase the risk of seizure or influence hemodynamic response
* Presence of any other condition that has the potential to prevent study completion and/or have a confounding effect on the interpretation of results.
Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

National Institute of Mental Health (NIMH)

NIH

Sponsor Role collaborator

Allyson Rosen

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Allyson Rosen

Neuropsychologist

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Allyson C Rosen, Ph.D.

Role: PRINCIPAL_INVESTIGATOR

PAVIR/Palo Alto VAHCS/Stanford University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

VA Palo Alto

Palo Alto, California, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

James Lavacot, BA

Role: CONTACT

6504935000 ext. 65651

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

James Lavacot, BA

Role: primary

650-493-5000 ext. 65651

Allyson C Rosen, PhD

Role: backup

650-512-3094

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MH129799

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

ROANEW_0004

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Improving Brain Stimulation Through Imaging
NCT03851380 ACTIVE_NOT_RECRUITING
TMS With Real-time E-field and EEG Source Imaging
NCT06645613 NOT_YET_RECRUITING NA
TMS-fNIRS Personalized Dosing
NCT05916417 RECRUITING NA
Functional Connectivity as a Biomarker of rTMS
NCT03050801 COMPLETED PHASE1/PHASE2